The Apparent Effects of Ziprasidone on Plasma Lipids and Glucose

Steven J. Kingsbury, Mohamed Fayek, Dorina Trufasiu, Jaafar Zada, and George M. Simpson

Published: May 1, 2001

Article Abstract

Background: We examined the effects of ziprasidone on body mass index (BMI) and serum levels of glucose, cholesterol, and triglycerides.

Method: As part of a multicenter study examining different strategies for switching to ziprasidone from other antipsychotics, we evaluated weight and serum glucose, cholesterol, and triglyceride measurements at baseline and following 6 weeks on ziprasidone treatment in 37 patients at our site.

Results: Short-term treatment with ziprasidone appeared to lead to significant reduction in serum cholesterol (p< .001) and triglyceride levels (p = .018) independent of changes in BMI. Ziprasidone treatment appeared to have no significant effect on BMI or glucose level, perhaps due to the small number of subjects.

Conclusion: Ziprasidone appears to independently lead to a lowering of serum lipid levels.

Volume: 62

Quick Links: Metabolic Disorder , Side Effects-Medication

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF


Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...